BACKGROUND: This study was performed to identify new significant prognostic factors in breast cancer patients irradiated for metastatic spinal cord compression (MSCC). PATIENTS AND METHODS: The data of 504 patients with breast cancer patients with MSCC were retrospectively analyzed with respect to posttreatment motor function, local control of MSCC, and survival. The investigated potential prognostic factors included age, Eastern Cooperative Oncology Group (ECOG) performance score, number of involved vertebrae, other bone metastases, visceral metastases, pretreatment ambulatory status, interval from cancer diagnosis to radiotherapy of MSCC, time developing motor deficits before radiotherapy, and the radiation schedule. RESULTS: On multivariate analysis, better functional outcome was associated with ambulatory status prior to RT (estimate - 1.29, p < 0.001), no visceral metastases (estimate - 0.52, p = 0.020), and slower development of motor deficits (estimate + 2.47, p < 0.001). Improved local control was significantly associated with no other bone metastases (risk ratio (RR) 4.33, 95% confidence interval (CI) 1.36-14.02, p = 0.013) and no visceral metastases (RR 3.02, 95% CI 1.42-6.40, p = 0.005). Improved survival was significantly associated with involvement of only 1-2 vertebrae (RR 1.27, 95% CI 1.01-1.60, p = 0.044), ambulatory status before radiotherapy (RR 1.75, 95% CI 1.23-2.50, p = 0.002), no other bone metastases (RR 1.93, 95% CI 1.18-3.13, p = 0.009), no visceral metastases (RR 7.60, 95% CI 5.39-10.84, p < 0.001), and time developing motor deficits before radiotherapy (RR 1.55, 95% CI 1.30-1.86, p < 0.001). CONCLUSION: Several new independent prognostic factors were identified for treatment outcomes. These prognostic factors should be considered in future trials and may be used to develop prognostic scores for breast cancer patients with MSCC.
BACKGROUND: This study was performed to identify new significant prognostic factors in breast cancerpatients irradiated for metastatic spinal cord compression (MSCC). PATIENTS AND METHODS: The data of 504 patients with breast cancerpatients with MSCC were retrospectively analyzed with respect to posttreatment motor function, local control of MSCC, and survival. The investigated potential prognostic factors included age, Eastern Cooperative Oncology Group (ECOG) performance score, number of involved vertebrae, other bone metastases, visceral metastases, pretreatment ambulatory status, interval from cancer diagnosis to radiotherapy of MSCC, time developing motor deficits before radiotherapy, and the radiation schedule. RESULTS: On multivariate analysis, better functional outcome was associated with ambulatory status prior to RT (estimate - 1.29, p < 0.001), no visceral metastases (estimate - 0.52, p = 0.020), and slower development of motor deficits (estimate + 2.47, p < 0.001). Improved local control was significantly associated with no other bone metastases (risk ratio (RR) 4.33, 95% confidence interval (CI) 1.36-14.02, p = 0.013) and no visceral metastases (RR 3.02, 95% CI 1.42-6.40, p = 0.005). Improved survival was significantly associated with involvement of only 1-2 vertebrae (RR 1.27, 95% CI 1.01-1.60, p = 0.044), ambulatory status before radiotherapy (RR 1.75, 95% CI 1.23-2.50, p = 0.002), no other bone metastases (RR 1.93, 95% CI 1.18-3.13, p = 0.009), no visceral metastases (RR 7.60, 95% CI 5.39-10.84, p < 0.001), and time developing motor deficits before radiotherapy (RR 1.55, 95% CI 1.30-1.86, p < 0.001). CONCLUSION: Several new independent prognostic factors were identified for treatment outcomes. These prognostic factors should be considered in future trials and may be used to develop prognostic scores for breast cancerpatients with MSCC.
Authors: E Maranzano; P Latini; E Perrucci; S Beneventi; M Lupattelli; E Corgna Journal: Int J Radiat Oncol Biol Phys Date: 1997-07-15 Impact factor: 7.038
Authors: Dirk Rades; Stefan Huttenlocher; Amira Bajrovic; Johann H Karstens; Irenaeus A Adamietz; Nadja Kazic; Volker Rudat; Steven E Schild Journal: Int J Radiat Oncol Biol Phys Date: 2011-01-27 Impact factor: 7.038
Authors: Dirk Rades; Theo Veninga; Lukas J A Stalpers; Rainer Schulte; Peter J Hoskin; Philip Poortmans; Steven E Schild; Volker Rudat Journal: Int J Radiat Oncol Biol Phys Date: 2005-09-28 Impact factor: 7.038
Authors: D Rades; S Douglas; T Veninga; A Bajrovic; L J A Stalpers; P J Hoskin; V Rudat; S E Schild Journal: Strahlenther Onkol Date: 2012-02-25 Impact factor: 3.621
Authors: L Bollen; G C W de Ruiter; W Pondaag; M P Arts; M Fiocco; T J T Hazen; W C Peul; P D S Dijkstra Journal: Eur Spine J Date: 2013-03-02 Impact factor: 3.134
Authors: Frederick Mantel; Stefan Glatz; André Toussaint; Michael Flentje; Matthias Guckenberger Journal: Strahlenther Onkol Date: 2014-06-27 Impact factor: 3.621
Authors: Amir Bahrami-Ahmadi; Fariborz Makarian; Mohammad R Mortazavizadeh; Mohammad F Yazdi; Mehdi Chamani Journal: J Res Med Sci Date: 2012-09 Impact factor: 1.852
Authors: Ingmar Schlampp; Stefan Rieken; Daniel Habermehl; Thomas Bruckner; Robert Förster; Jürgen Debus; Harald Rief Journal: Strahlenther Onkol Date: 2014-04-01 Impact factor: 3.621
Authors: Jeong Il Yu; Hee Chul Park; Yong Chan Ahn; Yoonsun Chung; Woong Sub Koom; Si Yeol Song Journal: Cancer Res Treat Date: 2015-12-02 Impact factor: 4.679